Stock comparison
ResMed
TransMedics Group
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
RMD
ResMed
Market cap
$29.57B
Sector
Healthcare
TMDX
TransMedics Group
Market cap
$2.18B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | RMD | TMDX | Winner |
|---|---|---|---|
| Warren Buffett | 64C | 51C | RMD |
| Benjamin Graham | 67B | 55C | RMD |
| Philip Fisher | 67B | 54C | RMD |
| Peter Lynch | 50C | 87A | TMDX |
| Joel Greenblatt | 39D | 42D | TMDX |
| Charlie Munger | 61C | 48D | RMD |
| Terry Smith | 65B | 41D | RMD |
Side-by-side metrics
| Metric | RMD | TMDX |
|---|---|---|
| Market cap | $29.57B | $2.18B |
| P/E (TTM) | 19.6x | 12.6x |
| EV/EBIT | 17.1x | 23.4x |
| ROIC (TTM) | 19.63% | 6.94% |
| Gross margin | 61.69% | 59.09% |
| Net margin | 27.44% | 27.04% |
| Revenue CAGR 5y | 12.64% | 111.5% |
| EPS CAGR 5y | 30.73% | - |
| Debt / Equity | 0.1x | 1.7x |
| Dividend yield | 1.14% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
RMD leads on
- Dividend yield1.14%vs 0.0%+100%
- Market cap$29.57Bvs $2.18B+93%
- Debt / Equity0.1xvs 1.7x+92%
- ROIC (TTM)19.63%vs 6.94%+65%
TMDX leads on
- Revenue CAGR 5y111.5%vs 12.64%+89%
- P/E (TTM)12.6xvs 19.6x+36%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.